← Back to all trials
Recruiting
NCT07192211
Exploratory Study of ADR-002K for Heart Failure Patients With Ischemic Heart Disease Who Undergo CABG
Conditions: Ischemic Heart Disease
Sex: All
Ages: 18 Years – 80 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 50
Sponsor: Rohto Pharmaceutical Co., Ltd.
Location: The University of Osaka Hospital Osaka Suita
Summary
ADR-002K is administered to heart failure patients with ischemic heart disease who undergo coronary artery bypass surgery (CABG) to investigate its efficacy and safety.
Eligibility Criteria
Inclusion Criteria:
1. Patients clinically diagnosed with chronic heart failure due to ischemic heart disease who undergo CABG
2. Patients with an LVEF of less than 40% as determined by the cardiac ultrasound at the screening examination.
3. Others
Exclusion Criteria:
1. Patients who have a combination of cardiovascular disease such as severe organic valvular disease.
2. Patients who have developed acute coronary syndrome within 3 months prior to obtaining consent.
3. Others
Source: ClinicalTrials.gov (NCT07192211). StuddyBuddy aggregates publicly available trial information.
